Justin Komisarof, MD, PhD
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor (Joint Appointment), Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Assistant Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2019 | University of Rochester Medical Center, Rochester, New York, US, Medicine and Dentistry, MD, PhD |
| 2009 | Harvard College, Biology, BA |
Postgraduate Training
| 2023-2026 | Fellowship of Hematology and Oncology, Hematology and Oncology, Baylor College of Medicine, Houston, Texas |
| 2019-2022 | Residency in Internal Medicine, Internal Medicine, University of Rochester Medical Center, Rochester, New York |
Licenses & Certifications
| 2026 | Texas Medical Board |
| 2025 | ACLS |
| 2022 | ABIM Certification in Internal Medicine |
Experience & Service
Other Professional Positions
Instructor, Oncology Hospitalist, University of Rochester Medical Center, Rochester, New York, 2022 - 2023
Biology Lecturer, Cancer Biology, Tsinghua-UC Berkeley Shenzhen Institute, Berkeley, California
Honors & Awards
| 2025 - Present | Cancer Prevention and Research Institute of Texas Training Award |
| 2023 - Present | Chessable Research Award |
| 2022 - Present | Raphael Dolin Resident Research Award |
| 2021 - Present | William L. Morgan Award |
| 2020 - 2021 | University of Rochester Medical Center ICARE Bronze Star |
Selected Presentations & Talks
Local Presentations
- 2025. Tumor-Board Style Discussion: Challenging Cases in Thoracic Oncology. Invited. Updates in Hematology and Oncology Conference.
Selected Publications
Peer-Reviewed Articles
- Komisarof J, Menon J, Andrzejewski A, Mulford D. Incidence and management of pyrexia syndrome in patients treated with dabrafenib and trametinib: a retrospective study. Support Care Cancer 34(4), 2026. e-Pub 2026. PMID: 41904738.
- Russo KA, Weeks S, Komisarof J, Zhang D, Levy D, Fung C. Spontaneous TLS Preceding the Diagnosis of Metastatic Prostate Cancer. Annals of Internal Medicine: Clinical Cases, 2024.
- Komisarof J, Forman J, Goldman B, Syposs C, Passero F, Garbade E. A Rare Case of Renal Thrombotic Microangiopathy and Focal Segmental Glomerulosclerosis Secondary to Plasma Cell Leukemia. Case Rep Hematol 2023:7803704, 2023. e-Pub 2023. PMID: 36852298.
- Komisarof J, Lipof J, DiTursi J, Chowdhry A, Grace Choung HY, Burack WR, Constine L, Passero F. An Unusual Case of Multiple Myeloma with Light-Chain Cast Nephropathy Secondary to a Very Large Plasmacytoma without Bone Marrow Involvement. Case Rep Hematol 2022:7531142, 2022. e-Pub 2022. PMID: 35237454.
- Superdock M, Komisarof J, Katerji H, Huselton E. Synchronous B-Cell Acute Lymphoblastic Leukemia and Serous Ovarian Carcinoma: A Case Report. Case Rep Oncol 14(3):1621-1626, 2021. e-Pub 2021. PMID: 34950006.
- Komisarof J, Qiu H, Velez MJ, Mulford D. Anterior mediastinal large cell neuroendocrine carcinoma with elevated AFP: A case report and review. Mol Clin Oncol 14(2):34, 2021. e-Pub 2021. PMID: 33414915.
- Komisarof J, McGann K, Huston A, Katerji H, Morgan MA. An Atypical Presentation of Hemophagocytic Lymphohistiocytosis (HLH) Secondary to Occult Hodgkin Lymphoma. Case Rep Hematol 2021:6672257, 2021. e-Pub 2021. PMID: 34341690.
- Komisarof J, McCall M, Newman L, Bshara W, Mohler JL, Morrison C, Land H. A four gene signature predictive of recurrent prostate cancer. Oncotarget 8(2):3430-3440, 2017. e-Pub 2017. PMID: 27966447.
- Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, O'Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Ribeiro U Jr, Marie SK, Dahl O, Shivdasani RA, Tsao MS, Rubin MA, Wong KK, Regev A, Hahn WC, Beer DG, Rustgi AK, Meyerson M. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41(11):1238-42, 2009. e-Pub 2009. PMID: 19801978.
- Turk BE, Lee DH, Yamakoshi Y, Klingenhoff A, Reichenberger E, Wright JT, Simmer JP, Komisarof JA, Cantley LC, Bartlett JD. MMP-20 is predominately a tooth-specific enzyme with a deep catalytic pocket that hydrolyzes type V collagen. Biochemistry 45(12):3863-74, 2006. e-Pub 2006. PMID: 16548514.
Other Articles
- Komisarof J, Qiu H, Velez MJ, Mulford D Erratum: Anterior mediastinal large cell neuroendocrine carcinoma with elevated AFP: A case report and review. Mol Clin Oncol 14(4):86, 2021. PMID: 33758667.
Abstracts
- Dowst H, McOwiti A, Madrid A, Zheng K, Komisarof J, Musher B, Liu H, Wang L. Multimodal Multi-Agent AI for Extraction of Pancreatic Cancer Treatment Response from Real-World Clinical Data. e-Pub 2026.
- Kvale E, Kanzler KK, Komisarof J, Schear E, Vasconcelos LM, Rodriguez N, Grouls A, Patel M. Lung Cancer Survivorship Care Codesign Using the AHEAD Framework. J Pain Symptom Manage 71(6):e1109-e1110, 2026. e-Pub 2026.
- Komisarof J, Menon J, Andrzejewski A, Mulford D. Outcomes of patients treated with dabrafenib and trametinib who developed pyrexia syndrome and severe/complicated pyrexia syndrome. J Clin Oncol 43:e24092-e24092, 2025. e-Pub 2025.
- Sabescumar J, Komisarof J, Levy D, Goldman B. The Masquerading Diagnosis of Secondary Thrombotic Microangiopathy. J Am Soc Nephrol 31(10S):834, 2020. e-Pub 2020.
- Dowst H, McOwiti A, Madrid A, Zheng K, Komisarof J, Musher B, Liu H, Wang L. Multimodal Multi-Agent AI for Extraction of Pancreatic Cancer Treatment Response from Real-World Clinical Data. American Medical Informatics Association Annual Symposium.
Patient Reviews
CV information above last modified October 01, 2026